Eli Lilly announced positive top-line results from Transcend‑T2D‑1: retatrutide—a triple agonist targeting GIP, GLP‑1 and glucagon receptors—met primary and key secondary endpoints in a Phase III trial for type 2 diabetes, delivering up to a 2.0% A1C reduction and mean weight loss of roughly 16.8% (~36.6 lb) at 40 weeks on the highest dose. The company reported safety consistent with GLP‑class agents. Investigators framed the data as a potential step-change in metabolic disease therapy because triple-receptor agonists aim to combine robust glycemic control with profound weight loss. Regulators will review full datasets for safety, tolerability and durability; if confirmed, retatrutide could shift standards for diabetes and obesity management and spur competitive responses across the incretin class. Clarification: Triple-agonists target three hormone receptors (GIP, GLP‑1, glucagon) to simultaneously affect appetite, glucose control and energy expenditure.